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Omega-3 and omega-6 PUFAs induce the same
GPR120-mediated signalling events, but with
different kinetics and intensity in Caco-2 cells
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Abstract
Background: Omega-3 PUFAs are known to have anti-inflammatory properties, and different mechanisms are
involved. GPR120 is a G-protein coupled receptor that has recently received attention because of its
anti-inflammatory signalling properties after binding omega-3 PUFAs. However, both omega-3 and omega-6 PUFAs
are natural GPR120 ligands. The aim of this study was to study possible differences in GPR120-mediated signalling
events after treatment with different long-chain PUFAs in intestinal epithelial cells. We also investigated possible
GPR120-mediated anti-inflammatory effects of different long-chain PUFAs that may be relevant in the
understanding of how dietary PUFAs influence inflammatory responses in inflammatory diseases such as IBD.
Methods: We used Caco-2 cells as a model system to study GPR120-mediated signalling events because we found
this cell line to express GPR120, but not GPR40, another plasma membrane receptor for medium- and long chain
fatty acids. Increase in cytosolic Ca2+concentration, activation of MAP kinase ERK1/2 and the inhibition of IL-1β
induced NF-κB activity were studied to reveal potential differences in the activation of GPR120 by the omega-3
PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and the omega-6 PUFA arachidonic acid (AA).
Results: We found that EPA, DHA and AA enhanced the cytosolic concentration of the second messenger
Ca2+ with the same efficiency, but with different kinetics. Both omega-3 and omega-6 PUFAs activated MAP kinase
ERK1/2, but differences regarding kinetics and intensity were also observed in this pathway. ERK1/2 activation was
shown to be dependent upon EGFR and Raf-1. We further investigated the ability of EPA, DHA and AA to inhibit
NF-κB activity in Caco-2 cells. All PUFAs tested were able to inhibit IL-1β induced breakdown of IκBα after binding
to GPR120, but with different potency.
Conclusions: Our results show that EPA, DHA and AA elicit the same signalling events, but with different kinetics
and efficiency through GPR120 in Caco-2 cells. We show, for the first time, that both omega-3 and omega-6 PUFAs
inhibit NF-κB activation in intestinal epithelial cells. Our results may be important for understanding how dietary
PUFAs influence inflammatory processes relevant in delineating effects of PUFAs in the treatment of IBD.
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Introduction
During digestion, dietary triglycerides are cleaved into
monoglycerides and free fatty acids (FFAs). These FFAs
are important nutrients in the daily energy intake, but they
also act as signalling molecules mediating their effects
through both nuclear- and plasma membrane receptors.
Four FFA-binding G-protein coupled receptors (GPCRs)
have been characterized, which bind FFAs with different
chain lengths. FFAR2 (GPR43) and FFAR3 (GPR41) are
activated by short-chain fatty acids (SCFAs), mainly acet-
ate, propionate and butyrate, produced in colon by bac-
terial fermentation of indigestible carbohydrates [1,2].
GPR120 together with GPR40 (FFAR1) are activated by
saturated and unsaturated medium- (C6-C12) and long-
chain (C14-24) FFAs [3-6]. GPR40 is most abundantly
expressed in pancreatic β-cells where it contributes to the
regulation of insulin secretion [4,7,8]. GPR40 and GPR120
are both expressed in the gastrointestinal tract, where they
regulate digestion through the secretion of cholecystokinin
(CCK). In addition, they aid in insulin secretion by stimu-
lating the release of the incretin hormones, glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) [4,6,9,10].
Polyunsaturated fatty acids (PUFAs) are principally di-
vided into the omega-6 and the omega-3 families. Lino-
leic acid (LA) and arachidonic acid (AA) are essential
omega-6 fatty acids and α-linolenic acid (ALA), eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA)
are essential omega-3 fatty acids. Omega-3 fatty acids
are generally considered anti-inflammatory, and different
mechanisms are described. Incorporation of omega-3
fatty acids in the cell membrane lowers the content of
AA, and thereby the substrate for synthesis of AA-derived
eicosanoids, which are generally considered more pro-
inflammatory than eicosanoids derived from EPA.
The transcription factor NF-κB is a key regulator of in-
flammation, and activation of NF-κB plays a key role in
the initiation and perpetuation of the inflammatory dis-
eases, including Crohn’s disease and Ulcerative colitis,
collectively named inflammatory bowel diseases (IBDs).
Omega-3 fatty acids reduce NF-κB mediated inflamma-
tory signals, an effect that has been linked to the activa-
tion of peroxisome proliferator activated receptor -γ
(PPAR-γ) and GPR120 [11-13]. Because of its anti-
inflammatory properties, dietary supplementation of
omega-3 PUFAs has been recommended in the treat-
ment of patients with IBD. Animal studies have demon-
strated beneficial effects from omega-3 PUFAs in the
treatment of IBD [14-19], but results from human clin-
ical trials are inconsistent with no clear evidence of effi-
cacy [20]. However, in vitro studies have shown that
omega-3 PUFAs exert anti-inflammatory effects in intes-
tinal epithelial cells [21,22]. Thus, there is a need to know
more about how omega-3 PUFAs interact with intestinal
epithelial cells in order to understand how omega-3
PUFAs may have beneficial effects and to optimize the use
of omega-3 PUFAs, in the treatment of IBD.
Omega-3 and omega-6 PUFAs are both natural ligands
of GPR120, but recent review articles refer to its anti-
inflammatory properties upon binding omega-3 PUFAs
only [23,24]. GPR120 is expressed in the gastrointestinal
tract, and the aim of this study was to elucidate signal-
ling pathways activated by omega-3 and omega-6 PUFAs
in intestinal epithelial cells. Caco-2 cells were used as a
model system to study GPR120 signalling in intestinal
epithelial cells. We further investigated the ability of
both omega-3 and omega-6 PUFAs to inhibit NF-κB ac-
tivation after binding to GPR120 on Caco-2 cells.
Results
PCR
PUFAs are natural ligands of GPR120 and GPR40. mRNA
for GPR120 was detected in normal tissue both from
ileum and colon, and in the Caco-2 cell line (Figure 1). On
the other hand, GPR40 was only detected in the ileum and
colon, which made Caco-2 cells a suitable system to spe-
cifically study PUFA-induced activation of GPR120.
PUFAs elevate the cytosolic Ca2+ concentration
Studies describing GPR120 signalling in different cellular
systems, including intestinal epithelial cells, have revealed
that GPR120 is coupled to Gαq [6,10,25]. However,
GPR120 has not been described in Caco-2 cells previously.
Since [Ca2+]i can be used as a measure of Gαq activity, we
investigated whether stimulation with EPA, DHA and AA
was able to enhance [Ca2+]i in Caco-2 cells.
Figure 2 shows that treatment with 200 μM EPA,
DHA or AA transiently increased [Ca2+]i in Caco-2 cells.
During treatment with the different PUFAs, the max-
imum increase of F360/F380, which monitors [Ca2+]i
were 52.2 ± 2.4% compared to untreated cells with EPA,
48.9 ± 1.8% with DHA, and 51.5 ± 2.6% with AA, and
there were no significant differences between the re-
sponses to the three fatty acids (Figure 2B). However,
Figure 1 Detection of GPR120 and GPR40 mRNA using PCR.
Total mRNA was isolated from tissue samples and Caco-2 cells using
Qiagen RNase Mini Kit. Rplp0 is a housekeeping gene, and was used
as a control. Each sample was analyzed in duplicates. The PCR
products were visualised using 1% agarose gel electrophoresis.
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Figure 2C shows that the time to peak (defined as time
from 10% to 90% of max F360/F380 ratio increase) of
[Ca2+]i during treatment with 200 μM EPA was 33.4 ±
4.4 sec, and significantly (P < 0.05) faster than the time
to peak of [Ca2+]i after treatment with 200 μM DHA
which was 61.8 ± 6.7 sec. The time to peak of [Ca2+]i
after treatment with 200 μM AA was 45.4 ± 7.7 sec, and
was not significantly different from the time to peak of
[Ca2+]i after treatment with 200 μM DHA or EPA.
The time from the start of treatment with the different
PUFAs, until the increase in [Ca2+]i started (defined as
time from start of treatment to 10% of max F360/F380
ratio increase), was also measured. Figure 2D shows that
the delay after treatment 200 μM EPA was 22.5 ± 4.3
sec, and significantly shorter compared to treatment
with both 200 μM DHA and 200 μM AA. The delay
after treatment with 200 μM DHA and AA were 42.2 ±
5.9 sec and 51.2 ± 6.4 sec respectively.
Activation of MAP kinase ERK1/2
Since differences were observed in the ability of the
PUFAs to enhance cytosolic Ca2+- levels, we wanted to
investigate whether such differences could also be
detected in other signalling pathways. GPR120 is known
to activate MAP kinase ERK1/2 in different cellular sys-
tems [6,11,26], and we therefore investigated if triggering
of GPR120 with EPA, DHA or AA would activate ERK1/
2 in Caco-2 cells. Figure 3A shows that treatment with
100 μM EPA, DHA or AA in 20 min enhanced ERK1/2
activity significantly (p < 0.5) in Caco-2 cells. Interest-
ingly, the activation induced by 100 μM DHA at 20 min
was stronger compared to treatment with EPA and AA,
although not statistically significant using densitometry.
Treatment with 100 μM EPA or DHA resulted in similar
kinetics in the activation of ERK1/2, while AA gave a
slower response (Figure 3B).
GPCRs can activate MAP kinase ERK1/2 through dif-
ferent mechanisms. To scrutinize possible pathways in-
volved in ERK1/2 activation induced by EPA, we used
the PKA inhibitor H89, the Raf-1 inhibitor GW5074 and
the EGF receptor inhibitor Gifitinib “Iressa”. Pretreat-
ment with 10 μM H89 for 1 h before treatment with 100
μM EPA for 20 min, did not affect ERK1/2 activation.
However, pretreatment with 10 μM GW5074 and 100
nM Iressa 1 h before treatment with 100 μM EPA for 20
min, abolished ERK1/2 activity compared to treatment
with 100 μM EPA alone (Figure 3C).
Anti-inflammatory properties of PUFAs
GPR120 has been shown to inhibit NF-κB signalling in-
duced by lipopolysaccharide (LPS) after binding to
Toll-like receptor 4 (TLR4) on macrophages and adipo-
cytes, due to binding of β-arrestin2 in complex with
transforming growth factor-β-activated kinase-1 (TAK1)
and TAK1 binding protein-1 (TAB1) [11]. TLR4 and IL-1
receptor are members of the same superfamily and they
use the same adaptors and kinases in their signalling path-
ways which lead to activation of NF-κB [27]. Since IL-1β is
known to activate NF-κB signalling in Caco-2 cells [28],
we investigated whether activation of GPR120 would in-
fluence IL-1β induced NF-κB activity in these cells. Treat-
ment with 10 ng/ml IL-1β for 30 min decreased IκBα
Figure 2 Effect of PUFAs on [Ca2+]i in Caco-2 cells. (A) Traces represent the effect of treating Caco-2 cells with 200 μM EPA, DHA and AA.
F360/F380 is the ratio between emissions at the two different excitation wavelengths and reflects [Ca2+]i. PUFAs were applied for 10–30 sec from
the time indicated by the vertical line. (B) The maximum [Ca2+]i response obtained after treatment with the different PUFAs, estimated as %
increase above baseline. (C) The time to peak of [Ca2+]i, measured as the time between 10% and 90% of maximum increase of [Ca
2+]i. (D) The
delay in seconds from start of treatment with indicated PUFAs until the increase of [Ca2+]i had reached 10% of maximum [Ca
2+]i. Data is
presented as mean ± SEM from n = 15 (EPA), 14 (DHA) and 10 (AA) cells.
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expression in Caco-2 cells compared to untreated cells.
Stimulation with EPA or AA, but not DHA, inhibited IL-
1β induced breakdown of IκBα significantly (p < 0.05)
compared to treatment with IL-1β alone. Even though the
PUFAs inhibited IL-1β induced breakdown of IκBα with
different efficiencies, these differences were not considered
significant compared to each other (Figure 4A).
Since activation of MAP kinase ERK1/2 was dependent
upon EGF receptor transactivation and Raf-1 activation,
we tested whether these were involved in the ability of
GPR120 to inhibit IL-1β induced breakdown of IκBα.
Figure 4B shows that neither Raf-1 nor the EGF receptor
are involved in the ability of EPA to inhibit IL-1β induced
breakdown of IκBα.
Discussion
Results from this study show that triggering of GPR120 with
EPA, DHA or AA in Caco-2 cells activated three independ-
ent intracellular signalling events; accumulation of cytosolic
Ca2+, EGF receptor- and Raf-1-dependent activation of
MAP kinase ERK1/2, and EGF receptor- and Raf-1-
independent inhibition of IL-1β induced NF-κB activation.
Interestingly, EPA, DHA and AA were able to activate these
pathways with different kinetics and intensity.
The finding that GPR120 activates Gαq and the subse-
quent increase of cytosolic Ca2+ are in agreement with
previous studies in other cellular systems [6,11,25,29]. In
the first study to describe induction of GPR120 signalling
by FFAs, EPA and DHA were shown to have almost equal
ability to enhance [Ca2+]i in HEK293 cells transfected with
GPR120 [6]. Oh et al. (2010) used GPR120-transfected
HEK293 cells to study accumulation of cytosolic Ca2+ after
treatment with FFAs, and found that EPA and DHA en-
hanced [Ca2+]i with same intensity. However, AA did not
enhance [Ca2+]i in this study [11]. We found that EPA,
DHA and AA were all able to enhance [Ca2+]i with the
same efficiency, but with different kinetics. The finding
that EPA was able to enhance [Ca2+]i faster than DHA
and AA may be due to differences in ligand affinity to
GPR120 on Caco-2 cells.
The differences in Ca2+ signalling dynamics induced
by the different PUFAs, did not correlate with the activa-
tion of pERK 1/2 induced by the same PUFAs. AA in-
duced a slower pERK 1/2 kinetic response than EPA and
DHA. DHA gave strongest pERK 1/2 activation after 20
min of treatment compared to AA and EPA, but these
differences were not considered significant. We further
show that the activation of pERK 1/2 is a result of EGF
Figure 3 The effect of PUFAs on ERK1/2 activation in Caco-2 cells. (A) Cells were treated with 100 μM EPA, DHA and AA for 20 min.
Differences in pERK 1/2 activity were determined using densitometry compared to untreated cells (n = 3, * p < 0.05, ** p < 0.01). (B) Cells were
treated with 100 μM EPA and DHA from 0–60 min, and 100 μM AA from 0–90 min. (C) Cells were pretreated for 1 h with 10 μM H89, 10 μM
GW5074 and 100 nM Iressa before treatment with 100 μM EPA for 20 min. The lysates were subjected to Western blotting to detect
phosphorylated ERK1/2 and total actin. The figure is representative for at least three experiments with similar results.
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receptor transactivation involving Raf-1 kinase. Long-
chain PUFAs are known to activate EGF receptor in
other cellular systems [30,31], but this activation has not
been linked to GPR120. In the present study, we show
that pretreatment with the EGF receptor specific inhibi-
tor Iressa, and Raf-1 inhibitor GW5074 abolish ERK1/2
activation induced by EPA. Raf-1 is a crucial kinase in
the MAP kinase signalling cascade leading to activation
of ERK1/2. EGF receptor can activate the Ras-Raf-Mek
cascade through the activation of Grb2 and SOS. The
finding that PKA inhibitor H89 did not influence ERK1/2
activity is in line with previous studies describing GPR120
signalling, where no study has reported activation of PKA
after GPR120 activation.
Both cytosolic Ca2+ increase and pERK1/2 activation
are involved in GPR120-induced secretion of GLP-1 and
CCK from intestinal cells [6,10,32,33]. The findings that
these pathways are activated differently by EPA, DHA
and AA in Caco-2 cells might gain new insights into var-
iations in the different PUFAs ability to induce the secre-
tion of GLP-1 and CCK.
Increased dietary intake of omega-6 PUFAs, and a lower
dietary intake of omega-3 PUFAs are though to contribute
to the development of IBD [34,35]. There is clear evidence
that omega-6 PUFAs exert pro-inflammatory events com-
pared to omega-3 PUFAs [34]. However, our results sug-
gest that both omega-3 and omega-6 PUFAs exert the
same anti-inflammatory effects by inhibiting NF-κB activ-
ity after binding GPR120 on Caco-2 cells. DHA, EPA and
AA were all able to inhibit IL-1β induced breakdown of
IκBα, but EPA and AA mediated the strongest inhibitory
effects. Since this effect was independent of Raf-1 and
EGF receptor, we speculate whether GPR120 may inhibit
IL-1β signalling in the same manner as TLR4 signalling.
These findings challenge the view that only omega-3
PUFAs exert anti-inflammatory effects after binding
GPR120. Our results may also be important in the under-
standing of how long-chain PUFAs, not only omega-3
PUFAs influence the inflammatory response in patients
with IBD.
In conclusion, our results show that both omega-3 and
omega-6 PUFAs activate the same GPR120-mediated sig-
nalling events in Caco-2 cells, but differences regarding
intensity and kinetics were observed. Previously, anti-
inflammatory effects of GPR120 have only been linked to
omega-3 PUFAs. We show, for the first time that they
might be linked to both omega-3 and omega-6 PUFAs.
Materials and methods
Materials
Sodium salts of arachidonic acid, docosahexaenoic acid
and eicosapentaenoic acid were from Sigma-Aldrich. Anti-
bodies targeted against Phospho-p44/42 MAPK (ERK1/2)
and IκBα were from Cell Signaling Technology and the
antibody targeted against α-actin was from Sigma-Aldrich.
HRP-conjugated secondary antibodies, Goat Anti-Mouse
IgG (H+L) and Goat Anti-Rabbit IgG (H+L) were from
Southern Biotech. Other chemicals used were: H89 from
Alexis Chemicals, GW5074 from Sigma-Aldrich and
Gefinib “Iressa” from Selleck Chemicals LLC.
Cell culture
The human colon adenocarcinoma cell line Caco-2
(ATTC; HTG-37TM) were grown in RPMI-1640
supplemented with 10% fetal calf serum (FCS), 100 μM
non-essential amino acids, 1 mM sodium pyruvate (all
from PAA Laboratories), and gentamicin (24 mg/l)
(Lonza). Cells were maintained in a humidified incubator
at 37°C and 5% CO2.
Figure 4 The effect of PUFAs on IL-1β induced degradation of
IκBα in Caco-2 cells. (A) Cells were treated with 100 μM EPA, DHA,
AA for 1 h, or with 100 ng/ml IL-1β for 30 min, or with 100 μM EPA,
DHA, AA for 1 hour and then treated with 100 ng/ml IL-1β for 30
min. Differences in IκBα expression were determined using
densitometry and compared to untreated cells (n = 3, * p < 0.05).
(B) Cells were pretreated with 10 μM GW5074 and 100 nM Iressa for
1 h before treatment with 100 μM EPA for 1 h and then treated
with 100 ng/ml IL-1β for 30 min. Cells were also treated with only
100 μM EPA, 10 μM GW5074 and 100 nM Iressa for 1 h and 100 ng/
ml IL-1β for 30 min. The lysates were subjected to Western blotting
to detect total IκBα and actin. The figure is representative for at least
three experiments with similar results.
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PCR
RNA from both tissue and cells were isolated using Qiagen
RNase Mini kit (Qiagen). Complementary DNA (cDNA)
was synthesized with Super ScriptW ViloTM (Applied
Biosystems) using 20 μl of reaction mixture containing 2
μg RNA. PCR was set up using TaqManWMaster Mix and
TaqManW probes: GPR120 (Hs00699184_m1), GPR40
(Hs03045166_s1) and rplp0 (Hs99999902_m1). 50 ng tem-
plate was used in each reaction.
Cytosolic Ca2+ measurements
Measurements of the cytosolic Ca2+ concentration were
performed in the following extracellular solution (EC):
150 mM NaCl, 5 mM KCl, 2.4 mM CaCl2, 1.3 mM
MgCl2, 10 mM glucose and 10 mM HEPES, adjusted to
pH 7.4 by NaOH.
Approximately 106 Caco-2 cells were seeded out
in collagen-coated glass-bottom dishes (MatTek
Coorporation) 3–4 days prior to experiment. Cells
were loaded with 5 μM of the fluorescent Ca2+ indica-
tor fura-2/AM (Molecular Probes) in EC for 45 min
at 37°C, followed by washout of the fura-2 ester and fur-
ther 30 min incubation at room temperature. Then, cells
were mounted on an Olympus OSP-3 system for dual ex-
citation fluorometry (Olympus). The excitation light was
switched at 200 Hz between 360 and 380 nm using a ro-
tating mirror. The emitted fluorescence was recorded at
510 nm with a photomultiplier, and the measurements
were restricted to single cells by a pinhole diaphragm. The
ratio between emissions at the two different excitation
wavelengths (F360/F380) reflects the cytosolic Ca2+ con-
centration [Ca2+]i. In the present study, the relative in-
crease in [Ca2+]i is used as a measure of the response to
the PUFAs. Therefore, calibration in order to determine
the absolute Ca2+ concentrations was not performed. Cells
were exposed to the different PUFAs by pressure ejection
(about 1 kPa) from a micropipette placed about 40 μm
from the cell. As negative control, cells were exposed to
EC by pressure ejection using the same conditions as de-
scribed above. No artefacts were observed when ejecting
normal EC onto cells, and the increase in [Ca2+]i was com-
pared to untreated cells.
Cell stimulation and lysis
Sodium salts of DHA, EPA and AA were dissolved in
autoclaved deionized water and further diluted in RPMI
1640. 0.5 × 106 cells were seeded per well in a 24-well
plate. The day after, the cells were serum-starved for 24
h in RPMI-1640 supplemented with 1% FCS, and then
stimulated as indicated. After stimulation, the cells were
lysed in 100 μl lysis buffer (25 mM Tris, pH7.5, 1% NP-
40, 100 mM NaCl, 20 mM NaF, 1 mM orthovanadate,
1 μg/ml leupeptin, 1 μg/ml antipain, 1 μg/ml pepstatin
A and 1 μg/ml chymostatin )per well for 30 min at 4°C.
Lysates were spun at 4°C for 15 min at 15 000 rpm, and
the supernatants were used for Western blotting.
Western blotting
Cell lysates were electrophoresed in 10% SDS-
polyacrylamide gels. The separated proteins were trans-
ferred to PVDF membranes by Western blotting. Upon
blotting, the membranes were blocked with 5% non-fat
dry milk for 1 h, and probed with specific antibodies to de-
tect protein of interest. LuminataTM Crescendo Western
HRP Substrate (Merck Millipore) was used as substrate
for HRP-conjugated secondary antibodies, and the mem-
branes were exposed using X-Ray film (Pierce). Densitom-
etry analysis was performed using Image J 1.46r. Adj.
density was obtained by comparing the intensity of the
band of interest with the intensity of the actin band from
the same sample.
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